<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368704</url>
  </required_header>
  <id_info>
    <org_study_id>GLUCOSTRESS P 08 11 22</org_study_id>
    <nct_id>NCT02368704</nct_id>
  </id_info>
  <brief_title>Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes</brief_title>
  <acronym>GLUCOSTRESS</acronym>
  <official_title>Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress pathway&#xD;
      is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic patients&#xD;
      compared to healthy subjects normoglycemic matched for age and sex an to investigate whether&#xD;
      ER stress pathway can be activated in response to insulin. Indeed, some preliminar on rates&#xD;
      studies shows that ER stress pathway is activated by insulin in liver and adipose tissue&#xD;
      showing that hyperinsulinemia might help trigger stress path ER.&#xD;
&#xD;
      For this, we propose a case control study of type 2 diabetic patients vs control subjects in&#xD;
      which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue&#xD;
      obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue&#xD;
      subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Show an increase in markers of ER stress in fasting patients with type 2 diabetes</measure>
    <time_frame>2 days</time_frame>
    <description>Protein expression markers of ER stress pathway BiP / GRP 78, CHOP, ATF4 EDEM and XBP-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess whether insulin induces an increase in markers of ER stress</measure>
    <time_frame>2 days</time_frame>
    <description>Insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion in response to glucose infusion</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion in response to arginine infusion</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipolysis on insulin</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Endoplasmic Reticulum Stress</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>control subjects with :&#xD;
Nondiabetic subjects (blood glucose &lt;7.0 mmol/l without hypoglycemic treatment).&#xD;
The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <description>Diabetic patients with :&#xD;
Having type 2 diabetes for at least 6 months&#xD;
HbA1c ≤ 8%&#xD;
Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin&#xD;
No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples. These samples will be anonymized, frozen and stored in the INSERM UMR-S 872 in&#xD;
      the Cordeliers Research Center (Madame Fabienne Foufelle) under the responsibility of&#xD;
      Professor Jean-François Gautier for a maximum period of 15 years, beyond which they will be&#xD;
      destroyed. These samples will be destroyed at any time at the request of the patient. This&#xD;
      DNA storage will be used to study genes related to the secretion of insulin and to identify&#xD;
      other genes involved in the onset of diabetes.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes Healthy volunteers Adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Specific criteria for diabetic patients:&#xD;
&#xD;
          -  Having type 2 diabetes for at least 6 months&#xD;
&#xD;
          -  HbA1c ≤ 8%&#xD;
&#xD;
          -  Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy&#xD;
             (metformin and / or sulfamid) and / or insulin secretors dependent glucose as&#xD;
             inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin&#xD;
&#xD;
          -  No modification of hypoglycemic therapy and / or insulin secretors for at least 3&#xD;
             months&#xD;
&#xD;
        Specific criteria for control subjects:&#xD;
&#xD;
          -  Nondiabetic subjects (fasting blood glucose &lt;7.0 mmol / l without hypoglycemic&#xD;
             treatment).&#xD;
&#xD;
          -  The control subjects should be matched to patients for age (± 5 years), sex, and BMI&#xD;
             (± 2 kg/m2).&#xD;
&#xD;
        Common criteria for patients and control subjects:&#xD;
&#xD;
          -  Aged 18 to 60 years&#xD;
&#xD;
          -  Body Mass Index between 25 and 35 kg/m2&#xD;
&#xD;
          -  Accepting the constraints of the protocol and who signed the informed consent&#xD;
&#xD;
          -  Systolic blood pressure &lt; 160 mmHg, diastolic blood pressure &lt; 90 mm Hg (with or&#xD;
             without antihypertensive treatment)&#xD;
&#xD;
          -  Resting heart rate between 55 and 100 beats/min.&#xD;
&#xD;
          -  Normal laboratory tests or not clinically significant abnormality for NFS platelets,&#xD;
             PT, aPTT, fibrinogen ALT, AST, GGT, Serum electrolytes, urea, creatinine, Uric acid&#xD;
             Triglycerides, total cholesterol, HDL cholesterol&#xD;
&#xD;
          -  HCG negative blood (for female subjects)&#xD;
&#xD;
          -  Affiliated to the Social Security.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current infections or recent infections (&lt;10 days)&#xD;
&#xD;
          -  Neoplastic disorders (with the exception of carcinoma in situ of the cervix or&#xD;
             cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological&#xD;
&#xD;
          -  Poisoning smoking (&gt;10 cigarettes per day, what ever the duration of intoxication)&#xD;
&#xD;
          -  Treatment with insulin or glitazones Pregnancy, Breastfeeding&#xD;
&#xD;
          -  Body Mass Index &gt; 35 kg/m2&#xD;
&#xD;
          -  Any drug taken for less than 8 days without the inclusion of minor analgesics&#xD;
             (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin&#xD;
             and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4&#xD;
             (dipeptidyl peptidase-4) and oral contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 15, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoplasmic Reticulum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

